# US 2023/0056202 A1 · Anti-malarial agents

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0056202 A1
- Document ID: US20230056202A1
- Status: Published application
- Kind: A1
- Application number: 17/787,378
- Filed: 2020-12-18
- Published: 2023-02-23
- Earliest claimed: 2019-12-20
- Assignees: Board of Regents, The University of Texas System; Mmv Medicines for Malaria Venture
- Applicants: The Board of Regents of the University of Texas System; Mmv Medicines for Malaria Venture
- Inventors: MARGARET PHILLIPS; MICHAEL PALMER; SUSAN A. CHARMAN; KARL SHAWN WATTS; ALEKSEY I. GERASYUTO; GORAN KRILOV
- Web page: https://patentgrep.com/patent/US20230056202A1

## CPC

- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/122: having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
- A61K 31/137: Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone}
- A61K 31/155: Amidines ([IMAGE cpc-sch-A61K-1029.gif]), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
- A61K 31/357: having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K 31/366: having six-membered rings, e.g. delta-lactones
- A61K 31/4162: condensed with heterocyclic ring systems
- A61K 31/4196: 1,2,4-Triazoles
- A61K 31/4706: 4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
- A61K 31/4709: Non-condensed quinolines and containing further heterocyclic rings
- A61K 31/473: ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
- A61K 31/4745: condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines (yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48)
- A61K 31/65: Tetracyclines
- A61P 33/06: Antimalarials
- C07D 207/34: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D 401/14: containing three or more hetero rings
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- C07D 413/14: containing three or more hetero rings
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention is related to new pyrrole derivatives in the manufacture of a medicament for preventing or treating malaria. Specifically, the present invention is related to pyrrole derivatives useful for the preparation of a pharmaceutical formulation for the inhibition of malaria parasite proliferation.

## Claims

### Claim at position 1

1-24. (canceled)

### Claim 25

A compound according to Formula (I):
wherein R1 is an optionally substituted 5-membered heterocycle such as an optionally substituted triazole, such as optionally substituted 1, 2, 4 triazole (e.g. 1, 2, 4 triazole), or optionally substituted pyrazole (1H-pyrazole-5-carboxamide) such as optionally substituted pyrazole-4-yl (e.g. 1H-pyrazol-4-yl, 1-methyl-pyrazol-4-yl) or optionally substituted pyrazole-3-yl (e.g. 5-methyl-1H-pyrazol-3yl, 5-cyano-1H-pyrazol-3-yl) or an optionally substituted imidazole such as an optionally substituted imidazole-4-yl (e.g. imidazole-4-yl) or an optionally substituted isoxazole such as an optionally substituted isoxazol-3-yl (e.g. 5-methylisoxazol-3-yl); R2 is H or both R2 are joined to form an optionally substituted cyclopropyl; R3 is selected from an optionally substituted monocyclic aryl such as an optionally substituted phenyl (3-fluoro-4-(trifluoromethyl)phenyl) and an optionally substituted heteroaryl such as optionally substituted pyridinyl, for example optionally substituted pyridin-3-yl (e.g. trifluoromethyl) pyridin-3-yl, di-fluoro-methyl pyridin-3-yl; as well as pharmaceutically acceptable salts, hydrates, solvates, tautomers, polymorphs, racemic mixtures, optically active forms and pharmaceutically active derivative thereof.

### Claim 26 (depends on 25)

A compound according to claim 25, wherein R1 is an optionally substituted triazole, such as optionally substituted 1, 2, 4 triazole.

### Claim 27 (depends on 25)

A compound according to claim 25, wherein R1 is an optionally substituted pyrazole.

### Claim 28 (depends on 25)

A compound according to claim 25, wherein R1 is an optionally substituted imidazole such as an optionally substituted imidazole-4-yl.

### Claim 29 (depends on 25)

A compound according to claim 25, wherein R1 is an optionally substituted isoxazole such as an optionally substituted isoxazol-3-yl.

### Claim 30 (depends on 25)

A compound according to claim 25, wherein R2 is H.

### Claim 31 (depends on 25)

A compound according to claim 25, wherein both R2 are joined to form an optionally substituted cyclopropyl.

### Claim 32 (depends on 25)

A compound according to claim 25, wherein R3 is an optionally substituted monocyclic aryl such as an optionally substituted phenyl.

### Claim 33 (depends on 25)

A compound according to claim 25, wherein R3 is an optionally substituted heteroaryl.

### Claim 34 (depends on 25)

A compound according to claim 25, wherein R3 is an optionally substituted as optionally substituted pyridinyl.

### Claim 35 (depends on 25)

A compound according to claim 25, selected from the following group:
3-methyl-N-(1-(1H-1,2,4-triazol-3-yl)ethyl)-4-(1-(6-(trifluoromethyl)pyridin-3-yl) cyclopropyl)-1H-pyrrole-2-carboxamide;
N-(1-(1H-1,2,4-triazol-3-yl)ethyl)-4-(3-fluoro-4-(trifluoromethyl)benzyl)-3-methyl-1H-pyrrole-2-carboxamide;
6 N-(1-(1H-pyrazol-4-yl)ethyl)-3-methyl-4-(1-(6-(trifluoromethyl)pyridin-3-yl)cyclopropyl)-1H-pyrrole-2-carboxamide;
3-methyl-N-[1-(5-methyl-1H-pyrazol-3-yl)ethyl]-4-{1-[6-(trifluoromethyl)pyridine-3-yl]cyclopropyl}-1H-pyrrole-2-carboxamide;
3-(1-(3-methyl-4-(1-(6-(trifluoromethyl)pyridin-3-yl)cyclopropyl)-1H-pyrrole-2-carboxamido)ethyl)-1H-pyrazole-5-carboxamide;
N-(1-(5-cyano-1H-pyrazol-3-yl)ethyl)-3-methyl-4-(1-(6-(trifluoromethyl)pyridin-3-yl) cyclopropyl)-1H-pyrrole-2-carboxamide;
N-(1-(1H-imidazol-4-yl)ethyl)-3-methyl-4-(1-(6-(trifluoromethyl)pyridin-3-yl)cyclopropyl)-1H-pyrrole-2-carboxamide;
4-(1-(6-(difluoromethyl)pyridin-3-yl)cyclopropyl)-3-methyl-N-(1-(1H-1,2,4-triazol-3-yl) ethyl)-1H-pyrrole-2-carboxamide;
4-{1-[3-cyano-4-(trifluoromethyl)phenyl]cyclopropyl}-3-methyl-N-[1-(1H-1,2,4-triazol-3-yl) ethyl]-1H-pyrrole-2-carboxamide;
3-methyl-N-(1-(5-methylisoxazol-3-yl)ethyl)-4-((6-(trifluoromethyl)pyridin-3-yl)methyl)-1H-pyrrole-2-carboxamide;
3-methyl-N-(1-(1H-pyrazol-4-yl)ethyl)-4-((6-(trifluoromethyl)pyridin-3-yl)methyl)-1H-pyrrole-2-carboxamide; and
3-methyl-N-(1-(1-methyl-1H-pyrazol-4-yl)ethyl)-4-((6-(trifluoromethyl)pyridin-3-yl)methyl)-1H-pyrrole-2-carboxamide; as well as pharmaceutically acceptable salts, hydrates, solvates, tautomers, polymorphs, racemic mixtures, optically active forms and pharmaceutically active derivative thereof.

### Claim 36 (depends on 25)

A pharmaceutical formulation containing at least one compound according to claim 25 and a pharmaceutically acceptable carrier, diluent or excipient thereof.

### Claim 37 (depends on 35)

A pharmaceutical composition according to claim 35, further comprising an antimalarial co-agent.

### Claim 38 (depends on 37)

A pharmaceutical composition according to claim 37, wherein the co-agent is selected from artemisinin or an artemisinin and its derivatives, such as artemether or dihydroartemisinin, chloroquine, quinine, mefloquine, amodiaquine, atovaquone/proguanil, doxycycline, lumefantrine, piperaquine, pyronaridine, halofantrine, pyrimethamine-sulfadoxine, primaquine, quinacrine, doxycycline, atovaquone, proguanil hydrochloride, piperaquine, ferroquine, tafenoquine, arterolane, Spiro[3H-indole-3,1′-[1H]pyrido[3,4-b]indol]-2(1H)-one, 5,7′-dichloro-6′-fluoro-2′,3′,4′,9′-tetrahydro-3′-methyl-,(1′R,3'S)— (CAS Registry Number: 1193314-23-6),(2-(1,1-difluoroethyl)-5-methyl-N-[4-(pentafluoro-λ6-sulfanyl)phenyl]-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine) (CAS Registry Number: 1282041-94-4), Morpholine,4-[2-(4-cis-dispiro[cyclohexane-1,3′-[1,2,4]trioxolane-5′,2″-tricyclo [3.3.1.13,7]decan]-4-ylphenoxy)ethyl]- (CAS Registry Number: 1029939-86-3), [3,3′-Bipyridin]-2-amine, 5-[4-(methylsulfonyl)phenyl]-6′-(trifluoromethyl)- (CAS Registry Number: 1314883-11-8), Ethanone, 2-amino-1-[2-(4-fluorophenyl)-3-[(4-fluorophenyl)amino]-5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl]- (CAS Registry Number 1261109-90-3).

### Claim 39 (depends on 25)

A method for preparing a compound of Formula (Ia), i.e. of Formula (I) wherein both R2 are joined to form an optionally substituted cyclopropyl, said method comprises transforming a compound according to Formula (X) into a compound of Formula (Ta), as follows:
wherein R1 and R3 are defined in claim 25.

### Claim 40 (depends on 25)

A method for preparing a compound of Formula (Ib), i.e. of Formula (I) wherein both R2 are H, said method comprises transforming a compound according to Formula (XI) in a compound of Formula (Ib) as follows:
wherein R1 and R3 are defined in claim 25.

### Claim 41 (depends on 25)

An intermediate of Formula (X)
wherein R3 is defined in claim 25.

### Claim 42 (depends on 41)

An intermediate of claim 41, selected from the following group:
3-methyl-4-(1-(6-(trifluoromethyl)pyridin-3-yl)cyclopropyl)-1H-pyrrole-2-carboxylic acid;
4-(3-fluoro-4-(trifluoromethyl)benzyl)-3-methyl-1H-pyrrole-2-carboxylic acid; and
4-(1-(6-(difluoromethyl)pyridin-3-yl)cyclopropyl)-3-methyl-1H-pyrrole-2-carboxylic acid.

### Claim 43 (depends on 25)

An intermediate of Formula (XI)
wherein R3 is defined in claim 25.

### Claim 44 (depends on 43)

An intermediate according to claim 43, wherein said intermediate is 3-methyl-4-((6-(trifluoromethyl)pyridin-3-yl)methyl)-1H-pyrrole-2-carboxylic acid.

### Claim 45 (depends on 25)

A method for preventing and/or treating malaria in a patient, said method comprising administering a derivative according to claim 25 or a pharmaceutical formulation thereof in a patient in need thereof.

### Claim 46 (depends on 45)

A method according to claim 45, wherein the said derivative is administered in combination with an antimalarial co-agent.
